Mycophenolate Mofetil Versus Azathioprine in Treatment Naive Autoimmune

Status Active, not recruiting

Clinical Trial Summary

Rationale: Current standard therapy of autoimmune hepatitis consists of a combination of prednisolone and azathioprine. However, a significant proportion of patients does not respond to, or is intolerant for, azathioprine. Mycophenolate mofetil (MMF) has surpassed azathioprine as therapy to prevent organ transplant rejection and is sometimes used as an alternative option for autoimmune hepatitis. Several case series and one prospective study have documented the efficacy and safety of mycophenolate mofetil as induction therapy for autoimmune hepatitis. Robust evidence from a formal randomized clinical trial is lacking. Objective: To assess the efficacy and safety of mycophenolate mofetil as induction therapy in patients with treatment naive autoimmune hepatitis. Study design: Multicenter, randomised, open-label intervention study Study population: Patients with newly diagnosed autoimmune hepatitis who are in need of induction therapy according to current guidelines. Intervention: The intervention group will receive oral mycophenolate mofetil for 24 weeks. The control group will be treated with azathioprine for 24 weeks. Both groups will be treated with steroid induction which will closely follow the schedule from the recent Clinical Practice Guidelines by the European Association for Study of the Liver (EASL). Main study parameters/endpoints: The primary outcome is the proportion of patients in biochemical remission, defined as normalization of serum alanine transaminase (ALT) and immunoglobulin G (IgG) levels after 24 weeks of treatment, per treatment group. Secondary endpoints include safety and tolerability of mycophenolate mofetil, time to remission, changes in Model For End-Stage Liver Disease (MELD) -score (and its components bilirubin, INR, creatinine), albumin, pseudocholinesterase and N-terminal procollagen-III-peptide, ELF (Enhanced Liver Fibrosis) -score and aspects of quality of life.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02900443
Study type	Interventional
Source	Radboud University Medical Center
Contact
Status	Active, not recruiting
Phase	Phase 4
Start date	January 2017
Completion date	June 2023

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT06020976` - Pattern of Autoimmune Hepatitis in Children In Sohag University Hospital
Recruiting	`NCT05476900` - A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Autoimmune Hepatitis.	Phase 2
Recruiting	`NCT05635266` - Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Recruiting	`NCT06250309` - Mediterranean Diet Versus Western Diet on Fatigue in Autoimmune Hepatitis Patients	N/A
Recruiting	`NCT01661842` - Umbilical Cord Mesenchymal Stem Cells for Patients With Autoimmune Hepatitis	Phase 1/Phase 2
Terminated	`NCT04339621` - AIH Risk Stratification With Multiparametric MRI
Not yet recruiting	`NCT04371718` - Effect of JKB-122 on Prednisolone and Azathioprine Induced Remission in Autoimmune Hepatitis (AIH)	Phase 2
Completed	`NCT02239562` - sPIF CLINICAL STUDY PROTOCOL IN AUTOIMMUNE HEPATITIS	Phase 1
Recruiting	`NCT05569759` - A Study of Zetomipzomib (KZR-616) in Patients With Autoimmune Hepatitis (PORTOLA)	Phase 2
Completed	`NCT02463331` - Association of Chloroquine and Prednisone as an Alternative Treatment for Autoimmune Hepatitis	Phase 4
Not yet recruiting	`NCT06356506` - A Study on Factors of Biochemical Response in Autoimmune Hepatitis
Terminated	`NCT04203875` - Abatacept for Treatment of Recurrent or de Novo Autoimmune Hepatitis	Phase 1
Recruiting	`NCT06078098` - Development of a Autoimmune Hepatitis Patient's Database Linked to a Biological Sample Storage
Completed	`NCT00838214` - Budesonide 3x3mg/d Versus Prednisone in Active Autoimmune Hepatitis	Phase 2/Phase 3
Recruiting	`NCT05810480` - PredIcting sterOid depeNdEnt livEr injuRy With Polyreactive Immunoglobulin G
Recruiting	`NCT03743272` - Repeatability and Reproducibility of Multiparametric MRI
Completed	`NCT03979053` - Quantitative Magnetic Resonance Imaging to Aid Clinical Decision Making in Autoimmune Hepatitis.
Not yet recruiting	`NCT04902807` - Conception of a Diagnosis, Prognosis and Therapeutic Decision Tool for Patients With Autoimmunity and Inflammation
Recruiting	`NCT04933292` - A Randomised Clinical Trial Assessing the Efficacy and Safety of Mycophenolate Mofetil Versus Azathioprine for Induction of Remission in Treatment Primary Biliary Cholangitis-Autoimmune Hepatitis Overlap Syndrome	Phase 4
Not yet recruiting	`NCT06455280` - SIPLIZUMAB in AILD and LT	Phase 1

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Mycophenolate Mofetil Versus Azathioprine in Treatment Naive Autoimmune Hepatitis — CAMARO

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms